Igenica, Inc. Awarded SBIR Grant For Next Generation Antibody Drug Conjugate Technology

BURLINGAME, Calif.--(BUSINESS WIRE)--Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), announced today the award of a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology. SNAP technology, named for its speed and ease of use, overcomes the major limitations of current approaches by providing a simple, chemically-driven method for linking any anti-cancer antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios of drug to antibody.

Help employers find you! Check out all the jobs and post your resume